#american society of clinical oncology

Collection of american society of clinical oncology news, found 10 news.

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's ...

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126

Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

LintonPharm to release data on Catumaxomab for advanced Gastric Cancer with peritoneal metastasis at 2022 ASCO Annual Meeting

LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging ...

Biden announces U.S. project to promote cancer data sharing

U.S. Vice President Joe Biden said  the "moonshot" initiative he leads aimed at finding cures for cancer was "the ...

SIRFLOX Study published in Journal of Clinical Oncology

-Prestigious ASCO Journal Publishes 530-patient SIRFLOX Study on SIR-Spheres® Y-90 resin microspheres in the ...

PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205- PEA PME eligible), a clinical-stage nanomedicine company pioneering ...

Berg Pharma presents at ASCO, poised to lead field in cancer metabolism

-     Berg Pharma, a Boston-based pharmaceutical company presented at the 2012 American Society of ...

Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metast

-      March 2011 Data Confirm Strong Treatment Effect of ...

Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy Shows a 64 % Risk Re

-        - Results of Phase III SAVE-ONCO Study Selected for "Best of ASCO 2011" ...

Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Result

- Phase I Data for NKP-1339, a First-in-Class Transferrin Targeted Anti-Cancer Agent to be Presented at Upcoming ...